Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study

Research output: Contribution to journalJournal articleResearchpeer-review

The use of positron emitter-labeled compounds for somatostatin receptor imaging (SRI) has become attractive because of the prospect of improved spatial resolution, accelerated imaging procedures, and the ability to quantify tissue radioactivity concentrations. This paper provides results from first-in-humans use of (64)Cu-DOTATATE, an avidly binding somatostatin receptor ligand linked to a radioisotope with intermediate half-life and favorable positron energy (half-life, 12.7 h; maximum positron energy, 0.653 MeV).
Original languageEnglish
JournalJournal of Nuclear Medicine
Issue number8
Pages (from-to)1207-15
Number of pages9
Publication statusPublished - Aug 2012

    Research areas

  • Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Neuroendocrine Tumors, Octreotide, Organometallic Compounds, Positron-Emission Tomography, Quality Control, Radiation Dosage, Radiochemistry, Tomography, Emission-Computed, Single-Photon

ID: 45863450